These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 3796837)

  • 1. Parkinson's disease and dementia: norepinephrine and dopamine in locus ceruleus.
    Cash R; Dennis T; L'Heureux R; Raisman R; Javoy-Agid F; Scatton B
    Neurology; 1987 Jan; 37(1):42-6. PubMed ID: 3796837
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serotonergic decompensation in the akinetic expression of Parkinson's disease.
    Iacono RP; Nahab FB; Nahab FH
    Int J Neurosci; 2000; 101(1-4):57-63. PubMed ID: 10765990
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The formation of deaminated metabolites of dopamine in the locus coeruleus depends upon noradrenergic neuronal activity.
    Curet O; Dennis T; Scatton B
    Brain Res; 1985 Jun; 335(2):297-301. PubMed ID: 2988695
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Central monoamine metabolism in depressions. II. Catecholamines and related compounds.
    van Praag HM
    Compr Psychiatry; 1980; 21(1):44-54. PubMed ID: 6987035
    [No Abstract]   [Full Text] [Related]  

  • 5. Behavioral and neurochemical effects of noradrenergic depletions with N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine in 6-hydroxydopamine-induced rat model of Parkinson's disease.
    Srinivasan J; Schmidt WJ
    Behav Brain Res; 2004 May; 151(1-2):191-9. PubMed ID: 15084435
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Striatal dopaminergic markers in dementia with Lewy bodies, Alzheimer's and Parkinson's diseases: rostrocaudal distribution.
    Piggott MA; Marshall EF; Thomas N; Lloyd S; Court JA; Jaros E; Burn D; Johnson M; Perry RH; McKeith IG; Ballard C; Perry EK
    Brain; 1999 Aug; 122 ( Pt 8)():1449-68. PubMed ID: 10430831
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biogenic amines in human brain in normal aging, senile dementia, and chronic alcoholism.
    Carlsson A; Adolfsson R; Aquilonius SM; Gottfries CG; Oreland L; Svennerholm L; Winblad B
    Adv Biochem Psychopharmacol; 1980; 23():295-304. PubMed ID: 6156586
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The functional anatomy of noradrenergic neurons in Parkinson's disease.
    Soldani P; Fornai F
    Funct Neurol; 1999; 14(2):97-109. PubMed ID: 10399622
    [No Abstract]   [Full Text] [Related]  

  • 9. Dysfunction of the locus coeruleus-norepinephrine system and related circuitry in Parkinson's disease-related dementia.
    Del Tredici K; Braak H
    J Neurol Neurosurg Psychiatry; 2013 Jul; 84(7):774-83. PubMed ID: 23064099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of local inhibition of locus coeruleus acetylcholinesterase by fasciculin in rats.
    Abó V; Viera L; Silveira R; Dajas F
    Neurosci Lett; 1989 Apr; 98(3):253-7. PubMed ID: 2471117
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in the brain catecholamines in patients with dementia of Alzheimer type.
    Adolfsson R; Gottfries CG; Roos BE; Winblad B
    Br J Psychiatry; 1979 Sep; 135():216-23. PubMed ID: 486847
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Altered serotonin metabolism in depressed patients with parkinson's disease.
    Mayeux R; Stern Y; Cote L; Williams JB
    Neurology; 1984 May; 34(5):642-6. PubMed ID: 6200801
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adrenergic receptors in Parkinson's disease.
    Cash R; Ruberg M; Raisman R; Agid Y
    Brain Res; 1984 Nov; 322(2):269-75. PubMed ID: 6095967
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of the locus coeruleus in the development of Parkinson's disease.
    Gesi M; Soldani P; Giorgi FS; Santinami A; Bonaccorsi I; Fornai F
    Neurosci Biobehav Rev; 2000 Aug; 24(6):655-68. PubMed ID: 10940440
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cathecholamines in the human brain and ageing.
    Adolfsson R; Gottfries CG; Roos BE; Winblad B
    Scand J Soc Med Suppl; 1977; 14():97-106. PubMed ID: 299010
    [No Abstract]   [Full Text] [Related]  

  • 16. Increased concentrations of 3-methoxy-4-hydroxyphenylethyl-eneglycol and homovanillic acid in rat brain after treatment with BE-2254 ("HEAT").
    Clineschmidt BV; Totaro JA; Pflueger AB; McGuffin JC
    J Pharm Pharmacol; 1975 Oct; 27(10):780-2. PubMed ID: 241795
    [No Abstract]   [Full Text] [Related]  

  • 17. Distribution of catecholamine uptake sites in human brain as determined by quantitative [3H] mazindol autoradiography.
    Donnan GA; Kaczmarczyk SJ; Paxinos G; Chilco PJ; Kalnins RM; Woodhouse DG; Mendelsohn FA
    J Comp Neurol; 1991 Feb; 304(3):419-34. PubMed ID: 2022757
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Noradrenergic alterations in Parkinson's disease: a combined 11C-yohimbine PET/neuromelanin MRI study.
    Laurencin C; Lancelot S; Brosse S; Mérida I; Redouté J; Greusard E; Lamberet L; Liotier V; Le Bars D; Costes N; Thobois S; Boulinguez P; Ballanger B
    Brain; 2024 Apr; 147(4):1377-1388. PubMed ID: 37787503
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Central levels of noradrenaline, 3-methoxy-4-hydroxyphenylethyleneglycol and cyclic AMP in the rat after activation of locus coeruleus neurons: influence of single and repeated neuroleptic treatment.
    Adèr JP; Sebens JB; Korf J
    Psychopharmacology (Berl); 1980; 70(3):239-45. PubMed ID: 6108589
    [No Abstract]   [Full Text] [Related]  

  • 20. A study of brain dopamine sulfate levels in relation to free dopamine and homovanillic acid in Parkinson's disease.
    Sofic E; Riederer P; Wesemann W; Kienzl E; Eichinger K; Gsell W; Jellinger K
    J Neural Transm Park Dis Dement Sect; 1991; 3(4):265-71. PubMed ID: 1772579
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.